Priority 17 from the Myeloma (Canada) PSP

UNCERTAINTY: How can minimal residual disease testing be applied in myeloma treatment to improve treatment efficacy and prognosis among people with myeloma? (JLA PSP Priority 17)
Overall ranking 17
JLA question ID 0113/17
Explanatory note Participants would like more research about the application of minimal residual disease (MRD) testing in the treatment of myeloma, including its use to tailor intensity and length of therapy, how to monitor MRD, and its role in prognosticating the disease.  
Evidence

No evidence identified
Health Research Classification System category Cancer and neoplasms
Extra information provided by this PSP
Original uncertainty examples How best to determine treatment effectiveness through next gen MRD testing. ~ MRD guided therapy to tailor to intensity and length of therapy. ~ Further studies which may improve the sensitivity of MRD testing in peripheral blood sample ~ Without knowing MRD , are we being overdosed or underdosed? ~ What is the long term prognosis for people with low M proteins that remain stable? ~ Why isn't every patient tested to see if they have residual disease in their body? ~ Does it make any difference if you have no  Mprotein detectable or if you have any in your blood after transplant?  
Submitted by Please see the PSP Engagement Summary on the JLA website  

~

PSP information
PSP unique ID 0113
PSP name Myeloma (Canada)
Total number of uncertainties identified by this PSP. 59  (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)
Date of priority setting workshop 28 April 2021